Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis
Open Access
- 6 November 2007
- journal article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 4 (11) , e292
- https://doi.org/10.1371/journal.pmed.0040292
Abstract
The time is now right for randomized trials of MDR-TB, say the authors, as the expansion of MDR-TB programs provides the setting in which trials can be implemented.Keywords
This publication has 31 references indexed in Scilit:
- XDR-TB in South Africa: No Time for Denial or ComplacencyPLoS Medicine, 2007
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaPublished by Elsevier ,2006
- Extensively Drug‐Resistant Tuberculosis: 2 Years of Surveillance in IranClinical Infectious Diseases, 2006
- Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the PhilippinesPLoS Medicine, 2006
- Multidrug-resistant Tuberculosis Management in Resource-limited SettingsEmerging Infectious Diseases, 2006
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- Cost-Effectiveness of Treating Multidrug-Resistant TuberculosisPLoS Medicine, 2006
- The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosisScience, 2006
- Imipenem for Treatment of Tuberculosis in Mice and HumansAntimicrobial Agents and Chemotherapy, 2005
- Treatment Experience of Multidrug-Resistant Tuberculosis in Florida, 1994–1997Chest, 2001